1

Surrozen

Surrozen
Leadership team

Mr. Craig C. Parker M.B.A. (CEO, Pres & Director)

Mr. Charles Williams (Chief Financial Officer)

Dr. Wen-Chen Yeh M.D., Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Emergency Medicine, Health Care
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2016
Company Registration
SEC CIK number: 0001824893
Traded as
NASDAQ:SRZN
Overview
Location
Summary
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
History

Surrozen was founded in 2013 with a mission to develop innovative therapies to treat debilitating patient conditions. The company raised a series A round of investment in March of 2014 and has since established a presence in the Bay Area. Over the past four years, the company has attracted significant scientific, clinical and healthcare partners while reaching several key milestones.

Mission
Our mission is to develop innovative and effective treatments that promote tissue repair and regeneration, which can give hope to people with serious medical conditions.
Vision
Our vision is to become the leader in regenerative medicine by developing breakthrough therapies that will improve patients’ lives.
Key Team

Dr. K. Christopher Garcia Ph.D. (Co-Founder & Member of Scientific Advisor)

Dr. Roeland Nusse Ph.D. (Co-Founder & Member of Scientific Advisor)

Dr. Calvin Kuo M.D., Ph.D. (Co-Founder & Member of Scientific Advisor)

Dr. Geertrui Vanhove M.B.A., M.D., Ph.D. (Chief Medical Officer)

Dr. Li Yang Ph.D. (Sr. VP of Biology)

Ms. Sheela Mohan-Peterson J.D., M.S. (Sr. VP of Legal, Gen. Counsel & Corp. Sec.)

Ms. Elizabeth Nguyen (Sr. VP and Head of Talent & Culture)

Recognition and Awards
Surrozen has won multiple awards including the 2016 Fierce Biotech Innovator Award and was listed as one of Fast Company’s Most Innovative Companies in Biotech in 2018.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Surrozen
Leadership team

Mr. Craig C. Parker M.B.A. (CEO, Pres & Director)

Mr. Charles Williams (Chief Financial Officer)

Dr. Wen-Chen Yeh M.D., Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Emergency Medicine, Health Care
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2016
Company Registration
SEC CIK number: 0001824893
Traded as
NASDAQ:SRZN